The overarching aim of this project (Phase 1 and 2) is to gain a greater understanding of the causes, clinical course and treatment of BD, examining the clinical, genetic and pharmacogenomic aspects of BD risk and response, as well as the determinants of general medical comorbidities in individuals with BD.
The specific aims of Phase 1 of the project are to:

  • Aim 1. Identify individuals with BD from administrative health data
  • Aim 2. Determine rates of common general health conditions in BD and non-BD populations
  • Aim 3. Determine whether higher rates (or greater severity) of comorbid general health conditions in BD correspond to treatment with particular medicines, or severity of BD
  • Aim 4. Examine the determinants of comorbidities and clinical course of BD illness